The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Antiva Biosciences, Pionyr Immunotherapeutics, Iconic Therapeutics. Among the most successful fund investment fields, there are Health Care, Biopharma.
Deals in the range of 5 - 10 millions dollars are the general things for fund. The top activity for fund was in 2018. The fund is constantly included in less than 2 deals per year.
The usual cause for the fund is to invest in rounds with more than 10 partakers. Despite the JLABS, startups are often financed by OUP (Osage University Partners), MPM Capital, Lundbeckfonden Ventures. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Sofinnova Investments, Sirona Capital.
Related Funds
| Fund Name | Location |
| Astomax Fund Management | Japan, Tokyo |
| BioExel | Galway, Ireland |
| BRD securities | - |
| Fengjia Capital Management | Beijing, Beijing, China |
| Georgian Pine Investments | California, Menlo Park, United States |
| INBlockchain | Beijing, Beijing, China |
| Kaas | - |
| Ningbo Meishan Bonded Port Chuangda Territory Investment Management | China, Ningbo, Zhejiang |
| Piramal Enterprises | India, Maharashtra, Mumbai |
| Plains Angels | Des Moines, Iowa, United States |
| Pride Capital Partners | Amsterdam, Noord-Holland, The Netherlands |
| Skycatcher | Austin, Texas, United States |
| Towerview Ventures | - |
| TriZetto | Colorado, Greenwood Village, United States |
| Universal Materials Incubator | Japan, Tokyo |
| Walton Street Capital | Chicago, Illinois, United States |
| Whitewater Bancorp | United States, Whitewater, Wisconsin |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Vincere Biosciences | $1M | 25 Nov 2020 | Cambridge, Massachusetts, United States | ||
Antiva Biosciences | $15M | 10 Jul 2018 | California, United States | ||
Mission Bio | 27 Jun 2018 | San Francisco, California, United States | |||
| $62M | 13 Dec 2017 | South San Francisco, California, United States | |||
Compass Therapeutics | 11 Jul 2017 | Boston, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Vincere Biosciences | $1M | 25 Nov 2020 | Cambridge, Massachusetts, United States | ||
Antiva Biosciences | $15M | 10 Jul 2018 | California, United States | ||
Mission Bio | 27 Jun 2018 | San Francisco, California, United States | |||
| $62M | 13 Dec 2017 | South San Francisco, California, United States | |||
Compass Therapeutics | 11 Jul 2017 | Boston, Massachusetts, United States |
